Nevertheless, the initial 960 mg dosage was confirmed from a regulatory point of view following the results of a post-marketing phase 2 comparing 960 mg (8 pills) to 240 mg (2 pills) in 209 patients with KRAS G12C mutated NSCLC [74]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.